nach oben

World Journal of Urology

Erschienen in:

31.08.2020 | Original Article

Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO

verfasst von: Mohamed G. Soliman, Shawky A. El-Abd, Ahmed M. Tawfik, Mohamed H. Radwan, Ahmed S. El-Abd

Erschienen in: World Journal of Urology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the efficacy and safety of mirabegron versus solifenacin as add-on for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.

Patients and methods

This prospective randomized single-blind study was conducted on patients with persistent OAB symptoms after at least 12 weeks of tamsulosin 0.4 mg. The patients were randomized into group A in which mirabegron (50 mg once daily) was added and group B in which solifenacin (5 mg once daily) was added. Before and 12 weeks after addition of either drugs, we assessed the efficacy of the treatment using the OABSS, IPSS, Q max, MVV/mic and PVR.

Results

Ninety two men were included in this study (46 patients in each group). All the study parameters were significantly improved after the 12-week treatment period in both groups except mean PVR which showed non-significant change in group A and a significant change in group B despite of being clinically irrelevant with only one case of acute urine retention. Overall, no significant difference has been observed between both groups after 12 weeks of treatment regarding all studied parameters except PVR. The incidence of side effects in group A was 10.9% versus 26.1% in group B. Main side effects included dry mouth in 2.2% and 8.7% and constipation in 2.2% and 6.5% in group A and B, respectively.

Conclusion

Our results indicate that the addition of either mirabegron or solifenacin to patients with persistent OAB symptoms after tamsulosin monotherapy has significant efficacy in controlling these symptoms. The adequate balance between efficacy and tolerability reported in this study with mirabegron may result in better QOL and overall patient satisfaction if compared with antimuscarinics.

Wang H, Chang Y, Liang H (2017) Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pak J Med Sci 33(4):988–992CrossRef

Abrams P et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49CrossRef

Masumori N et al (2010) The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol. https://doi.org/10.1155/2010/205251CrossRefPubMedPubMedCentral

Witjes WP et al (1997) The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother. J Urol 157(4):1295–1300CrossRef

Kaplan SA et al (2013) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63(1):158–165CrossRef

Wada N et al (2016) Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder. Low Urin Tract Symp 8(3):171–176CrossRef

Imran M, Najmi AK, Tabrez S (2013) Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy. Urol J 10(3):935–940PubMed

Khullar V et al (2013) Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol 63(2):283–295CrossRef

Chapple CR et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63(2):296–305CrossRef

10.

Matsuo T et al (2016) The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with alpha1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol 16(1):45CrossRef

11.

Otsuki H et al (2013) beta3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol 45(1):53–60CrossRef

12.

Warren K, Burden H, Abrams P (2016) Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf 7(5):204–216CrossRef

13.

Homma Y et al (2006) Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 68(2):318–323CrossRef

14.

Knutson T et al (2001) BPH with coexisting overactive bladder dysfunction—an everyday urological dilemma. Neurourol Urodyn 20(3):237–247CrossRef

15.

Chapple C et al (2009) Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 56(3):534–541CrossRef

16.

Takeda M et al (2013) Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite alpha-blocker treatment in patients with BPH: the ADDITION study. Urology 82(4):887–893CrossRef

17.

van Kerrebroeck P et al (2013) Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 64(6):1003–1012CrossRef

18.

Kumar V et al (2003) Recent developments in the management of detrusor overactivity. Curr Opin Urol 13(4):285–291CrossRef

19.

Ichihara K et al (2015) A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 193(3):921–926CrossRef

20.

Kakizaki H et al (2020) Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus 6(4):729–737CrossRef

21.

Abrams P et al (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175(3 Pt 1):999–1004 (discussion 1004)CrossRef

22.

Yamaguchi O et al (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology 78(1):126–133CrossRef

23.

Kaplan SA et al (2009) Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182(6):2825–2830CrossRef

24.

Nitti VW et al (2013) Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 190(4):1320–1327CrossRef

25.

Kaplan SA et al (2020) Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J Urol. https://doi.org/10.1097/JU.0000000000000738CrossRefPubMed

26.

Gacci M et al (2014) Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol 14:84CrossRef

27.

Wu ZL, Geng H (2009) Combination of tolterodine and tamsulosin for benign prostatic hyperplasia. Zhonghua Nan Ke Xue 15(7):639–641PubMed

28.

Yamaguchi O et al (2014) Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 113(6):951–960CrossRef

29.

Chapple CR et al (2014) Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol 21(10):960–967CrossRef

30.

Nitti VW et al (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189(4):1388–1395CrossRef

Titel: Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO
verfasst von: Mohamed G. Soliman
Shawky A. El-Abd
Ahmed M. Tawfik
Mohamed H. Radwan
Ahmed S. El-Abd
Publikationsdatum: 31.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2021
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03425-3

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis

Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)

Correction to: Consultation on kidney stones, Copenhagen 2019: lithotripsy in percutaneous nephrolithotomy

Informative value of histological assessment of tissue acquired during aquablation of the prostate